-+ 0.00%
-+ 0.00%
-+ 0.00%

VolitionRx Executes Non-Binding Letter Of Intent With Missionpharma A/S To Develop, Roll Out Volition's Prototype Lateral Flow Technology For NETosis

Benzinga·10/27/2026 12:52:40
Listen to the news

VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has executed a non-binding Letter of Intent ("LOI") with Missionpharma A/S, a Danish global leader in the sale and distribution of healthcare products and innovative solutions, impacting the lives of over 100 million patients annually, regarding the potential development and launch of Volition's prototype Lateral Flow Technology ("LFT") for NETosis.